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Abstract
Cardiogenic shock is a lethal condition. Physicians are searching
for hemodynamic markers which could help risk-stratification of
patients in this picture. Torgersen and coworkers present an hourly
time integral of the cardiac power index and cardiac index drops to
predict outcomes in the setting of cardiogenic shock. Continuous
monitoring of hemodynamic markers may have a role in prediction
of outcomes.
In the previous issue of Critical Care, Torgersen and
coworkers present data about careful evaluation of hemo-
dynamic monitoring of patients with cardiogenic shock (CS)
in the intensive care unit as continuous variables during the
initial 24-hour period [1]. Hemodynamic parameters
influencing short-term mortality were identified. The authors
stated that hourly time integrals of the cardiac index (CI)
(cardiac output per body surface area) and the cardiac power
index (CPI) (cardiac power output per body surface area)
were the most important hemodynamic variables designating
mortality as continuous parameters. In addition, instead of
intermittent measures of the CI and the CPI, the authors
analyzed the area under a given level divided into hourly
intervals, named hourly time integrals. These results have the
potential to provide a paradigm shift in the setting of CS.
Two take-home messages can be extracted from the study of
Torgersen and coworkers [1]. First is the emphasis on the
importance of continuous monitorization in patients with CS,
and the second message is providing data for the importance
of the interpretation of the CPI as a continuous variable in an
acute setting.
CS is traditionally defined as a state of severe tissue hypo-
perfusion secondary to cardiac dysfunction. It carries high
mortality risk, around 50% in the acute term [2]. Therefore, it
is vital to identify signals driving the CS prognosis. For
decades, hemodynamic monitoring has been desired for
patients with acute pathologies with the aim of guiding therapy
and risk-stratification [3]. Many parameters derived from
hemodynamics – such as the cardiac output, systemic blood
pressure, systemic vascular resistance, stroke volume, and
pulmonary capillary wedge pressure – have so far been
investigated to designate prognosis with unequivocal results
[4,5]. Among these hemodynamic parameters, the cardiac
power output and the CPI serve as interesting markers
showing cardiovascular coupling at one glance, in contrast to
other parameters that provide information about either the
cardiac system or the vascular system [5].
Drops in the CPI were described by Torgersen and
colleagues to predict outcome [1]. A critically low CPI might
be a result of unresponsiveness to therapeutic interventions
rather than a causative factor for death. One should mention
that although the hourly time integrals of drops in the CI and
CPI predicted short-term mortality, this might not mean that
the CI and the CPI are targets for treatment. Indeed, in many
cases, patients die despite high CI levels. Intra-aortic balloon
pump (IABP) use is known to increase cardiac power output,
and hence the CPI [6]. Adjustment should have been
performed for the use of an IABP (37.8% of patients).
Adjustment for gender was also needed, as the cardiac
power output is also lower in females [7]. In a very recent
meta-analysis, it was shown that a percutaneous left
ventricular assist device yielded higher CI and higher mean
arterial pressure compared with the IABP. This could be
translated as a higher CPI with the left ventricular assist
device compared with that under IABP use. The 30-day
mortality was similar in both interventions, however, despite
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better early hemodynamic status with the left ventricular
assist device [8]. A better CI or CPI may therefore not always
translate into better outcomes. Torgersen and coworkers
brought us some novel thresholds, however, which should be
tested in multicenter trials. Eventually, these thresholds can
serve as targets.
The present paper emphasizes the continuous effort that
should be made to risk-stratify patients with CS. Hemo-
dynamic variables are important to consider in the setting of
CS, particularly those parameters integrating generation of
cardiac energy with spreading of blood flow, such as the CPI.
Since it was shown that almost one-half of nonsurvivors of
CS die with a normal CI, this finding changed the paradigm of
CS recently from being only a cardiac problem into a disease
of the entire circulatory system [9,10]. Data tell us the
importance of systemic inflammatory response upon release
of inflammatory mediators and neurohormones yielding altera-
tions in tissue microvasculature, which may result in multi-
organ dysfunction syndrome in CS [11]. We therefore agree
that hemodynamic signals combining cardiac function with
tissue perfusion such as the CPI may be optimal markers of
outcome. On the contrary, it might be as important to consider
any invasive hemodynamic parameter as a continuous (and
not intermittent) marker, as presented by Torgersen and
coworkers, instead of considering them per piece.
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